Loss of morphine hyperphagia following neonatal monosodium glutamate treatment in rats

Area of Science:

• Neuroscience
• Neuroendocrinology
• Behavioral Neuroscience

Background:

• Morphine is known to stimulate food intake in rats.
• The medial-basal hypothalamus and circumventricular organs are involved in regulating feeding behaviors.
• Opioid pathways, particularly those involving beta-endorphin, are implicated in morphine-induced hyperphagia.

Purpose of the Study:

• To investigate the role of the medial-basal hypothalamus and circumventricular organs in morphine-induced hyperphagia.
• To determine if neonatal monosodium glutamate (MSG) treatment affects morphine's ability to stimulate food intake.
• To explore the involvement of opioid-related cells in the medial-basal hypothalamus in this effect.

Main Methods:

• Neonatal administration of monosodium glutamate (MSG) to rats to selectively damage specific brain regions.
• Assessment of food intake in both MSG-treated and control rats.
• Administration of varying doses of morphine (1.0-5.0 mg/kg, sc) or vehicle.
• Utilizing a mild food deprivation paradigm (5 hours).

Main Results:

• Morphine-induced hyperphagia (increased food intake) was absent in MSG-treated rats.
• MSG-treated rats responded normally to mild food deprivation when given a vehicle treatment.
• These findings indicate a specific deficit in the response to morphine, not a general feeding impairment.

Conclusions:

• The circumventricular system, particularly opioid-containing cells within the medial-basal hypothalamus, plays a significant role in mediating morphine-induced hyperphagia.
• Neonatal MSG treatment disrupts these pathways, leading to the absence of morphine's appetite-stimulating effects.
• This study highlights the importance of specific neuroanatomical structures in drug-induced behavioral changes.